SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/291666"
 

Search: onr:"swepub:oai:gup.ub.gu.se/291666" > Effects of dapaglif...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Docherty, Kieran F (author)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-03-28
  • Oxford University Press (OUP),2020

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/291666
  • https://gup.ub.gu.se/publication/291666URI
  • https://doi.org/10.1093/eurheartj/ehaa183DOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and reduced ejection fraction. We examined whether this benefit was consistent in relation to background HF therapy.In this post hoc analysis, we examined the effect of study treatment in the following yes/no subgroups: diuretic, digoxin, mineralocorticoid receptor antagonist (MRA), sacubitril/valsartan, ivabradine, implanted cardioverter-defibrillating (ICD) device, and cardiac resynchronization therapy. We also examined the effect of study drug according to angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose, beta-blocker (BB) dose, and MRA (≥50% and <50% of target dose). We analysed the primary composite endpoint of cardiovascular death or a worsening HF event. Most randomized patients (n=4744) were treated with a diuretic (84%), renin-angiotensin system (RAS) blocker (94%), and BB (96%); 52% of those taking a BB and 38% taking a RAS blocker were treated with ≥50% of the recommended dose. Overall, the dapagliflozin vs. placebo hazard ratio (HR) was 0.74 [95% confidence interval (CI) 0.65-0.85] for the primary composite endpoint (P<0.0001). The effect of dapagliflozin was consistent across all subgroups examined: the HR ranged from 0.57 to 0.86 for primary endpoint, with no significant randomized treatment-by-subgroup interaction. For example, the HR in patients taking a RAS blocker, BB, and MRA at baseline was 0.72 (95% CI 0.61-0.86) compared with 0.77 (95% CI 0.63-0.94) in those not on all three of these treatments (P-interaction 0.64).The benefit of dapagliflozin was consistent regardless of background therapy for HF.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Jhund, Pardeep S (author)
  • Inzucchi, Silvio E (author)
  • Köber, Lars (author)
  • Kosiborod, Mikhail N (author)
  • Martinez, Felipe A (author)
  • Ponikowski, Piotr (author)
  • DeMets, David L (author)
  • Sabatine, Marc S (author)
  • Bengtsson, Olof (author)
  • Sjöstrand, Mikaela (author)
  • Langkilde, Anna Maria,1955 (author)
  • Desai, Akshay S (author)
  • Diez, Mirta (author)
  • Howlett, Jonathan G (author)
  • Katova, Tzvetana (author)
  • Ljungman, Charlotta,1977Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xljcha (author)
  • O´Meara, Eileen (author)
  • Petrie, Mark C (author)
  • Schou, Morten (author)
  • Verma, Subodh (author)
  • Vinh, Pham Nguyen (author)
  • Solomon, Scott D (author)
  • McMurray, John J V (author)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för molekylär och klinisk medicin (creator_code:org_t)

Related titles

  • In:European heart journal: Oxford University Press (OUP)41:25, s. 2379-23921522-96450195-668X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view